Fallback Solo™ (levonorgestrel) Tablet, 1.5 mg
- Manufacturer
- Lupin Pharmaceuticals, Inc. | LUPIN LIMITED
- Effective date
- 2023-02-28
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 10
- Source
- legacy-cache
- Hydrated at
- 2026-08-01 21:30:47
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
Drug Facts
Active Ingredient
Levonorgestrel USP 1.5 mg
Purpose
Emergency contraceptive
Indications
Use for women to reduce chance of pregnancy after unprotected sex (if a contraceptive failed or if you did not use birth control).
Warnings
Allergy alert: Do not use if you have ever had an allergic reaction to levonorgestrel.
Sexually transmitted diseases (STDs) alert: This product does not protect against HIV/AIDS or other STDs
Do not use
- if you are already pregnant (because it will not work)
- for regular birth control
Ask a doctor or pharmacist before use if you are taking efavirenz (HIV medication) or rifampin (tuberculosis treatment) or medication for seizures (epilepsy). These medications may reduce the effectiveness of levonorgestrel.
When using this product you may have
- menstrual changes
- nausea
- lower stomach (abdominal) pain
- tiredness
- headache
- dizziness
- breast pain
- vomiting
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
This package is not child resistant. Keep this and all medication out of the reach of children.
In case of overdose, get medical help or contact a Poison Control center right away.
SPL UNCLASSIFIED SECTION
Directions
- take as soon as possible within 72 hours (3 days) after unprotected sex. The sooner you take it the better it will work.
- if you vomit within 2 hours after taking the medication, call a healthcare professional to find out if you should repeat the dose.
Other Information
- read the instructions, warnings and enclosed product leaflet before use .
- this product works mainly by preventing ovulation (egg release). It may also prevent fertilization of a released egg (joining of sperm and egg) or attachment of a fertilized egg to the uterus (implantation).
- tablet is enclosed in wallet seal. Do not use if the wallet seal is broken .
- store at 25°C (77°C); excursions permitted to 15 to 30°C (59 to 86°C) [see USP Controlled Room temperature].
Inactive Ingredients
colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate, and povidone.
SPL UNCLASSIFIED SECTION
Questions or comments?
For more information call 1800-399-2561 or visit our website at
www.birthcontrolhealth.com.
SPL UNCLASSIFIED SECTION
Fallback Solo™
(levonorgestrel) Tablet, 1.5 mg
Emergency Contraceptive
One Tablet. One Dose.
What You Need to Know
SPL UNCLASSIFIED SECTION
What is Fallback Solo™?
Fallback Solo™ is emergency contraception that helps prevent pregnancy after birth control failure or unprotected sex. It is a backup method of preventing pregnancy and should not be used as regular birth control.
What Fallback Solo is not.
Fallback Solo will not work if you are already pregnant and will not affect an existing pregnancy. Fallback Solo will not protect you from HIV infection (the virus that causes AIDS) and other sexually transmitted diseases (STDs).
When should I use Fallback Solo?
The sooner you take emergency contraception, the better it works. You should use Fallback Solo within 72 hours (3 days) after you have had unprotected sex.
Fallback Solo is a backup or emergency method of birth control you can use when:
- your regular birth control was used incorrectly or failed
- you did not use any birth control method
SPL UNCLASSIFIED SECTION
When not to use Fallback Solo?
Fallback Solo should not be used:
- as a regular birth control method, because it's not as effective as regular birth control.
- if you are already pregnant, because it will not work.
- if you are allergic to levonorgestrel or any other ingredients in Fallback Solo.
When should I talk to a doctor or pharmacist?
Ask a doctor or pharmacist before use if you are taking efavirenz (HIV medication) or rifampin (tuberculosis treatment) or medication for seizures (epilepsy). These medications may reduce the effectiveness of Fallback Solo and increase your chance of becoming pregnant. Your doctor may prescribe another form of emergency contraception that may not be affected by these medications.
How does Fallback Solo work?
Fallback Solo works before release of an egg from the ovary. As a result, Fallback Solo usually stops or delays the release of an egg from the ovary. Fallback Solo is one tablet that contains a higher dose of levonorgestrel than birth control pills and works in a similar way to prevent pregnancy.
How can I get the best results from Fallback Solo?
You have 72 hours (3 days) to try to prevent pregnancy after birth control failure or unprotected sex. The sooner you take Fallback Solo, the better it works.
How effective is Fallback Solo?
If Fallback Solo is taken as directed, it can significantly decrease the chance that you will get pregnant. About 7 out of every 8 women who would have gotten pregnant will not become pregnant.
How will I know Fallback Solo worked?
You will know Fallback Solo has been effective when you get your next period, which should come at the expected time, or within a week of the expected time. If your period is delayed beyond 1 week, it is possible you may be pregnant. You should get a pregnancy test and follow up with your healthcare professional.
Will I experience any side effects?
- some women may have changes in their period, such as a period that is heavier or lighter or a period that is early or late. If your period is more than a week late, you may be pregnant.
- If you have severe abdominal pain, you may have an ectopic pregnancy, and should get immediate medical attention.
- when used as directed, Fallback Solo is safe and effective. Side effects may include changes in your period, nausea, lower stomach (abdominal) pain, tiredness, headache, dizziness, and breast tenderness.
- if you vomit within 2 hours of taking the medication, call a healthcare professional to find out if you should repeat the dose.
What if I still have questions about Fallback Solo?
If you have questions or need more information, call our toll-free number, 1800-399-2561 or visit our website at
www.birthcontrolhealth.com.
Other Information
Keep this and all medication out of reach of children:
In case of overdose, get medical help or contact a Poison Control Center right away at 1-800-222-1222.
Do not use if the wallet seal is opened.
Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature].
Active Ingredient: levonorgestrel 1.5 mg
Inactive Ingredients: colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate, and povidone.
Fallback Solo™ is a trademark of Lupin Pharmaceuticals, Inc.
Distributed By:
Lupin Pharmaceuticals, Inc.
Baltimore, Maryland 21202
United States
Manufactured by:
Lupin Limited
Pithampur (M.P.) - 454 775
INDIA
Revised: May, 2023 ID#: 273480
If you are sexually active, you should see a healthcare provider for routine checkups. Your healthcare provider will talk to you about and, if necessary, test you for sexually transmitted diseases, teach you about effective methods of routine birth control, and answer any other questions you may have.
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
Fallback Solo™ (levonorgestrel) Tablet, 1.5 mg
NDC 68180-853-11
Wallet Label: 1 Tablet

Fallback Solo™ (levonorgestrel) Tablet, 1.5 mg
NDC 68180-853-13
Carton Label: 1 Tablet

DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 68180-853-11 | EA - Each | 68180-853 | a7e71e8c-c6de-4a8c-8c63-32f0a4264d58 | 1 | 2014-10-03 |
| 68180-853-13 | EA - Each | 68180-853 | 98033c05-e1c1-48a6-8eea-4c2b868e5a7a | 1 | 2014-10-03 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| LEVONORGESTREL | ACTIVE INGREDIENT | 5W7SIA7YZW | 3 | |
| LEVONORGESTREL | ACTIVE MOIETY | 5W7SIA7YZW | 3 | |
| COLLOIDAL SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 3 | |
| LACTOSE MONOHYDRATE | INACTIVE INGREDIENT | EWQ57Q8I5X | 3 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 3 | |
| POVIDONE K30 | INACTIVE INGREDIENT | U725QWY32X | 3 | |
| STARCH, CORN | INACTIVE INGREDIENT | O8232NY3SJ | 3 |
Products#
Every source-derived product name is available through these pages.
- Fallback Solo
- levonorgestrel
- LACTOSE MONOHYDRATE
- MAGNESIUM STEARATE
- POVIDONE K30
- SILICON DIOXIDE
- STARCH, CORN
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 68180-853 | 68180-853-11, 68180-853-13 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| LEVONORGESTREL | 5W7SIA7YZW | ACTIB |
| LACTOSE MONOHYDRATE | EWQ57Q8I5X | IACT |
| MAGNESIUM STEARATE | 70097M6I30 | IACT |
| POVIDONE K30 | U725QWY32X | IACT |
| SILICON DIOXIDE | ETJ7Z6XBU4 | IACT |
| STARCH, CORN | O8232NY3SJ | IACT |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | POWDER, FOR SUSPENSION / ORAL | NA | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | POWDER, FOR SUSPENSION / ORAL | 257 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CREAM / TOPICAL | NA | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 19 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, COATED / ORAL | 184 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | SUSPENSION / ORAL | 64 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, COATED / ORAL | 176 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | INSERT / VAGINAL | 8 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, DELAYED RELEASE PARTICLES / ORAL | 170 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, FOR SUSPENSION / ORAL | 200 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | DROPS / ORAL | NA | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | POWDER, FOR SUSPENSION / ORAL | 34 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / BUCCAL | 3 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | CAPSULE / ORAL | 5785 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INSERT / VAGINAL | 2282 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, COATED / ORAL | 1301 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 12 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, DELAYED RELEASE / ORAL | 144 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 47 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | IMPLANT / INTRAVITREAL | NA | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET / SUBLINGUAL | 409 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 107 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | TABLET, FOR SUSPENSION / ORAL | 462 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE / ORAL | 256.4 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SOLUTION / ORAL | 336 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET, DELAYED RELEASE / ORAL | 713 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | FILM / SUBLINGUAL | 7 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | WAFER / ORAL | 66 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | GRANULE, FOR SOLUTION / ORAL | 1691.8 mg/120ml | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / SUBLINGUAL | 17.5 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | INHALANT / ORAL | 0.08 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | INSERT / VAGINAL | 147 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | SUSPENSION, EXTENDED RELEASE / ORAL | 113 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 53 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION / INTRAMUSCULAR | 150 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SUSPENSION / ORAL | 400 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FOR SUSPENSION / ORAL | 131 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, ORALLY DISINTEGRATING / ORAL | 187 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | CAPSULE, EXTENDED RELEASE / ORAL | 5364 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / SUBLINGUAL | 505 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | TABLET / BUCCAL | 1 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / ORAL | 750 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | FILM, EXTENDED RELEASE / TRANSDERMAL | 16 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | IMPLANT / SUBCUTANEOUS | 0.5 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 9 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | SUSPENSION/ DROPS / ORAL | 90 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED PELLETS / ORAL | 69 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SUPPOSITORY / RECTAL | 14 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | SYSTEM / INTRAVITREAL | 0.02 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | GRANULE / ORAL | 202 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, FILM COATED / ORAL | 968 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | LOZENGE / ORAL | 700 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION / SUBCUTANEOUS | 98 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | INSERT / VAGINAL | 69 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | SOLUTION/ DROPS / OPHTHALMIC | 4 mg | ||
| COLLOIDAL SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TAMPON / VAGINAL | NA | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, FOR SUSPENSION / ORAL | 2794 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 9.5 %w/v | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | PELLET / ORAL | 640 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | GRANULE / ORAL | 629 mg |
Orange Book application contexts#
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A201446-001 | FALLBACK SOLO | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2014-06-19 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | c2088c7a36db… | ||
| 2026-09-14 22:38:34 | 2026-08 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A201446-001 | FALLBACK SOLO | 1.5MG | TABLET / ORAL | 2014-06-19 | 3a93d1ddd44b… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ce23e28b-2919-44d6-933f-09971f44b019 | 38c26cb9-052e-426f-9916-c13e7a5e62d0 | 2023-12-20 | Warnings | 38c26cb9-052e-426f-9916-c13e7a5e62d0 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.